Entering text into the input field will update the search result below

Palatin closes Rekynda license deal with AMAG Pharma; shares ahead 20% premarket

Feb. 03, 2017 7:57 AM ETPalatin Technologies, Inc. (PTN) StockBy: Douglas W. House, SA News Editor17 Comments
  • Palatin Technologies (NYSE:PTN) finalizes its license deal with AMAG Pharmaceutical (AMAG) for exclusive North American rights to develop and commercialize Rekynda (bremelanotide) for the on-demand treatment of premenopausal women with hypoactive sexual desire disorder (HSDD).
  • The company has received an initial payment of $60M under the agreement. Shares are up 20% premarket on increased volume.

Recommended For You

About PTN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
PTN--
Palatin Technologies, Inc.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.